Global Health vs Shalby vs Indegene: Which Stock Should You Track

Global Health PE 68.91, mkt cap Rs 38,059 crore. Shalby PE 40.94, mkt cap Rs 1,534 crore. Indegene PE 36.33, mkt cap Rs 14,566 crore.

Updated: 30 Sept 2026 • 10:10 am

Posted by:

Global Health vs Shalby vs Indegene: Which Stock Should You Track

Quick Answer

Global Health vs Shalby vs Indegene is a side-by-side comparison of three companies from the Hospitals space. On this comparison, Global Health carries a market capitalisation of about Rs 38,059 crore against Rs 1,534 crore for Shalby and Rs 14,566 crore for Indegene, with return on equity of 14.05%, 3.72% and 12.78% respectively. Each company's numbers are presented here without a declared better pick, since the right stock depends on an investor's own criteria.

Global Health vs Shalby vs Indegene starts with the core numbers most investors compare within the Hospitals segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Hospitals bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Table of Contents

Global Health, Shalby and Indegene: Company Overview

Global Health is a listed Indian company in the Hospitals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Shalby is a listed Indian company in the Hospitals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Indegene is a listed Indian company in the Hospitals space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Global Health vs Shalby vs Indegene: Valuation and Profitability Snapshot

Metric	Global Health	Shalby	Indegene
Market Cap (approx.)	Rs 38,059 crore	Rs 1,534 crore	Rs 14,566 crore
PE Ratio (TTM)	68.91	40.94	36.33
PB Ratio	9.61	1.53	4.64
Return on Equity (ROE)	14.05%	3.72%	12.78%
EPS (TTM, Rs)	20.54	3.47	16.64
Dividend Yield	0.04%	0.00%	0.37%
Debt to Equity	0.30	0.59	0.05
Book Value per Share (Rs)	147.34	93.11	130.27

Check the Univest Screener for Live Data

On valuation, Global Health trades at a PE of 68.91 and a PB of 9.61, Shalby at a PE of 40.94 and a PB of 1.53, while Indegene trades at a PE of 36.33 and a PB of 4.64. On return on equity, the three post 14.05%, 3.72% and 12.78% respectively, and on dividend yield they stand at 0.04%, 0.00% and 0.37%.

Global Health vs Shalby vs Indegene: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Global Health	Rs 1,326.21 crore	Rs 157.25 crore	+26.1%	+10.9%
Shalby	Rs 338.63 crore	Rs 10.50 crore	+11.6%	+14.6%
Indegene	Rs 1,092.10 crore	Rs 116.20 crore	+39.5%	+7.7%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Global Health, Shalby and Indegene live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three hospitals names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Global Health vs Shalby vs Indegene highlights how differently three companies in the same hospitals segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Global Health vs Shalby vs Indegene

What is the market cap difference between Global Health, Shalby and Indegene?

Ans. As of September 2026, Global Health has a market cap of approximately Rs 38,059 crore, Shalby is at approximately Rs 1,534 crore, and Indegene is at approximately Rs 14,566 crore.

Which of the three has the highest PE ratio?

Ans. Among Global Health, Shalby and Indegene, the PE ratios stand at 68.91, 40.94 and 36.33 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Global Health, Shalby and Indegene post ROE of 14.05%, 3.72% and 12.78% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Global Health, Shalby and Indegene carry dividend yields of 0.04%, 0.00% and 0.37% respectively.

What is the debt to equity ratio for Global Health, Shalby and Indegene?

Ans. Global Health carries a debt to equity of 0.30, Shalby of 0.59, and Indegene of 0.05.

Which of the three trades at the highest price to book value?

Ans. Global Health, Shalby and Indegene trade at price to book ratios of 9.61, 1.53 and 4.64 respectively.

Is one of Global Health, Shalby or Indegene better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.